Diteba

APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Probes, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.

Qualities
We pay the most careful attention to the quality of our products. All products are manufactured with rigorous guidelines and are accompanied with certificates of analysis, HPLC, Mass Spectrum, and HMNR, as well as in vitro validation. APExBIO products have been cited by many top peer-reviewed journals such as Nature, Cell and Science.

Services
Biologists and Chemists at APExBIO offer extensive tech support to our customers for using the products. You may expect personalized and attentive care from our support staff answering your order and technical inquiries. We also provide custom services including peptide synthesis, custom mRNA synthesis and assay development.

Located in the heart of Silicon Valley, Bayside BioSciences is a contract provider offering one-stop preclinical services for Biotech and Pharmaceutical industries to facilitate their drug development processes.
• Bayside BioSciences is committed to support our clients’ needs in preclinical development. This support includes services in bioanalytic, molecular and cell biology, in vitro and in vivo pharmacology.
• We will work closely with our sponsors with great flexibility, to start studies quickly to meet tight timelines, and to adjust study dates and designs as needed to optimize outcomes.
• Our capabilities include assay development and in vitro/in vivo pharmacology studies for antibodies, small molecules, siRNAs, proteins, and gene therapy products.

Empiriko Corporation, a biotech company that has developed a novel in vitro biomimetic platform to accelerate small molecule drug development with current focus on antiviral therapies. The company is also developing a point-of-care diagnostic platform for personalized immunologic/genetic biomarker and drug monitoring. The synergies between these platforms enables Empiriko to cost effectively accelerate drug development and customize patient treatment for improved clinical outcomes.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs.

Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

MedChem Partners is a medicinal chemistry CRO founded in 2006 by Tsvetelina Lazarova and Steven Riesinger. The company is focused on using the extensive experience in early stage company formation and drug discovery to effectively advance small molecule candidates for clients by working closely with the client’s biology and/or chemistry resources. Our experts have extensive experience in moving projects from inception through discovery and into development up to IND enabling toxicology.

At MedChem Partners, we are experts at using synthetic and medicinal chemistry to develop small molecule therapeutics. Unlike large one-stop shops that spread their attention over a variety of tasks, we focus on what we know best. Our expertise is in formulating and implementing a plan to find and optimize small molecules which interact with novel or known biological targets. Whether you already have potential molecules in mind, or have just discovered a novel target, we can develop a plan to find and optimize compounds with therapeutic potential. Since drug discovery is a multidisciplinary endeavor, we have foraged close contacts with a variety of other service providers to augment our expertise in certain areas. Since each company is focused on what it does best, this approach allows us to tap into the best talent in each area. Through out network we have access to in vitro and in vivo testing, in vitro and in vivo pharmacokinetics, computer modeling and in silico prediction, formulation, scale-up and manufacturing, toxicology and regulatory filing, x-ray crystallography, intellectual property and patenting, and consultants in clinical, regulatory, manufacturing, pharmacology, and toxicology.